CR20210629A - Esteroides neuroactivos y composiciones de estos - Google Patents
Esteroides neuroactivos y composiciones de estosInfo
- Publication number
- CR20210629A CR20210629A CR20210629A CR20210629A CR20210629A CR 20210629 A CR20210629 A CR 20210629A CR 20210629 A CR20210629 A CR 20210629A CR 20210629 A CR20210629 A CR 20210629A CR 20210629 A CR20210629 A CR 20210629A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sup
- compositions
- neuroactive steroids
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0095—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 carbon in position 21 is part of carboxylic group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
En el presente documento, se proporciona un compuesto de la Fórmula (I): o una sal farmacéuticamente aceptable de esta, donde R<sup>1a</sup>, R<sup>1b</sup>, R<sup>2a</sup>, R<sup>2b</sup>, R<sup>3</sup>, R<sup>4a</sup>, R<sup>4b</sup>, R<sup>5</sup>, R<sup>6a</sup>, R<sup>6b</sup>, R<sup>7a</sup>, R<sup>7a</sup>, R<sup>11a</sup>, R<sup>11b</sup>, R<sup>12a</sup>, R<sup>12b</sup>, R<sup>16a</sup>, R<sup>16b</sup>, R<sup>19</sup>, R<sup>11a</sup>, R<sup>22</sup>, R<sup>X</sup>, R<sup>Y</sup> y n se definen en el presente documento. También se proporcionan en el presente documento composiciones farmacéuticas que comprenden un compuesto de la Fórmula (I) y métodos de usar el compuesto, p. ej., en el tratamiento de trastornos relacionados con el SNC.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962855435P | 2019-05-31 | 2019-05-31 | |
PCT/US2020/035210 WO2020243488A1 (en) | 2019-05-31 | 2020-05-29 | Neuroactive steroids and compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210629A true CR20210629A (es) | 2022-03-22 |
Family
ID=71787077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210629A CR20210629A (es) | 2019-05-31 | 2020-05-29 | Esteroides neuroactivos y composiciones de estos |
Country Status (22)
Country | Link |
---|---|
US (2) | US11643434B2 (es) |
EP (1) | EP3976628A1 (es) |
JP (1) | JP2022534424A (es) |
KR (1) | KR20220016098A (es) |
CN (1) | CN114206900A (es) |
AR (1) | AR119047A1 (es) |
AU (1) | AU2020284110A1 (es) |
BR (1) | BR112021024033A2 (es) |
CA (1) | CA3139554A1 (es) |
CL (1) | CL2021003166A1 (es) |
CO (1) | CO2021015890A2 (es) |
CR (1) | CR20210629A (es) |
DO (1) | DOP2023000152A (es) |
EC (1) | ECSP21091076A (es) |
IL (1) | IL288410A (es) |
JO (1) | JOP20210293A1 (es) |
MA (1) | MA56046A (es) |
MX (1) | MX2021014515A (es) |
PE (1) | PE20230244A1 (es) |
SG (1) | SG11202112391UA (es) |
TW (1) | TW202110457A (es) |
WO (1) | WO2020243488A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2806877T1 (sl) | 2012-01-23 | 2020-01-31 | Sage Therapeutics, Inc. | Nevroaktivne steroidne formulacije, ki obsegajo kompleks alopregnanolona in sulfobutil etra beta-ciklodekstrina |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
SG11201901445TA (en) | 2016-08-23 | 2019-03-28 | Sage Therapeutics Inc | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
MX2021006618A (es) | 2018-12-05 | 2021-09-23 | Sage Therapeutics Inc | Esteroides neuroactivos y sus metodos de uso. |
MX2021014679A (es) | 2019-05-31 | 2022-04-06 | Janssen Pharmaceutica Nv | Inhibidores de molécula pequeña de quinasa inductora de nf-kb. |
BR112022013585A2 (pt) * | 2020-01-12 | 2022-09-13 | Brii Biosciences Inc | Esteroides neuroativos e composição farmacêutica que contém os mesmos |
CA3172901A1 (en) * | 2020-02-27 | 2021-09-02 | Brii Biosciences, Inc. | Prodrugs of neuroactive steroids |
Family Cites Families (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
FR1380417A (fr) | 1962-05-15 | 1964-12-04 | Roussel Uclaf | Nouveaux androstanyl-pyrazoles et procédé de préparation |
US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
FR2969M (fr) | 1963-05-22 | 1964-11-30 | Roussel Uclaf | Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale. |
BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
GB1380246A (en) | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
GB1434919A (en) | 1972-06-15 | 1976-05-12 | Glaxo Lab Ltd | 3alpha-hydroxy androstanes |
US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
GB1436324A (en) | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
ES432106A1 (es) | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
DE2438020A1 (de) | 1974-08-05 | 1976-02-26 | Schering Ag | 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung |
IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
EP0603312A4 (en) | 1991-09-13 | 1995-06-07 | Cocensys Inc | NEW GABA A RECEPTOR WITH STEROID BINDING POINTS. |
DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
EP0752860B1 (en) | 1994-02-14 | 2000-08-23 | Euro-Celtique S.A. | Androstanes and pregnanes for allosteric modulation of gaba receptor |
AU3125695A (en) | 1994-07-21 | 1996-02-22 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
BR9509764A (pt) | 1994-11-23 | 1998-07-07 | Cocensys Inc | Série androstano e pregnano para modulação alostérica de receptor de gaba |
ATE284895T1 (de) * | 1995-06-06 | 2005-01-15 | Euro Celtique Sa | Neuroaktive steroide der androstan- und pregnanreihe |
AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
WO2000066614A1 (en) | 1999-04-29 | 2000-11-09 | Purdue Pharma Ltd. | 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY |
US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
EP1172371B1 (en) | 2000-02-18 | 2005-06-08 | Taiho Pharmaceutical Company Limited | Process for the preparation of steroid derivatives |
US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
ES2287184T3 (es) | 2000-11-03 | 2007-12-16 | Washington University | Estructuras aromaticas modificadas con sustituyentes hidroxi-, que tienen actividad citoprotectora. |
GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
DK1608671T3 (da) | 2003-03-24 | 2010-05-10 | Sterix Ltd | Østrogenderivater som inhibitorer af steroidsulfatase |
WO2005000869A1 (en) | 2003-05-29 | 2005-01-06 | Washington University | Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
AU2004292555A1 (en) | 2003-11-24 | 2005-06-09 | Merck & Co., Inc. | Estrogen receptor modulators |
WO2005105822A2 (en) * | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
US20070014719A1 (en) | 2004-09-29 | 2007-01-18 | Reading Christopher L | Steroid analogs and characterization and treatment methods |
KR20100095661A (ko) | 2005-06-09 | 2010-08-31 | 유로-셀띠끄 소시에떼 아노님 | 신경 자극성 스테로이드의 약학적 조성물 및 그 용도 |
US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
WO2008157460A1 (en) | 2007-06-15 | 2008-12-24 | Cook, Kevin, M. | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
KR100958286B1 (ko) | 2007-11-15 | 2010-05-19 | 한국과학기술원 | a1G T―타입 칼슘 채널을 억제하여 본태성 진전증을예방 및 치료하는 방법 |
US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
CZ2008434A3 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
US20100120733A1 (en) | 2008-11-07 | 2010-05-13 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
AU2011284606A1 (en) | 2010-07-30 | 2013-03-14 | Pharmacellion Ltd | Compounds and methods for treating neoplasia |
US20120214987A1 (en) | 2010-12-15 | 2012-08-23 | Yu Ge | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
US9457033B2 (en) | 2011-02-15 | 2016-10-04 | Socpra Sciences Et Genie, S.E.C. | Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria |
CZ303443B6 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
WO2012116290A2 (en) | 2011-02-25 | 2012-08-30 | Washington University | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
EP2695948B1 (en) | 2011-03-23 | 2016-12-28 | Etsuro Ito | Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate |
CA2843436A1 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
LT2753632T (lt) | 2011-09-08 | 2023-07-10 | Sage Therapeutics, Inc. | Neuroaktyvieji steroidai, jų kompozicijos ir naudojimas |
EP2766380B1 (en) | 2011-10-14 | 2019-04-24 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
CN104781272A (zh) | 2012-06-19 | 2015-07-15 | 英特塞普特医药品公司 | 奥贝胆酸的制备、用途和固体形式 |
US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
EP2916846A4 (en) | 2012-11-09 | 2016-08-10 | Goodchild Invest Pty Ltd | NEUROACTIVE STEROIDS AND THEIR USE TO FACILITATE NEUROPROTECTION |
NZ739760A (en) | 2012-12-18 | 2020-05-29 | Univ Washington | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
CA2831054C (en) | 2013-01-09 | 2016-08-30 | Sapna Life Sciences Corp. | Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury |
GB201302368D0 (en) | 2013-02-11 | 2013-03-27 | Univ Bath | Compound |
US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
US9512165B2 (en) | 2013-04-17 | 2016-12-06 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
CN105246909B (zh) | 2013-04-17 | 2020-10-13 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
BR112016000975B1 (pt) | 2013-07-19 | 2020-10-06 | Sage Therapeutics, Inc. | Compostos esteróides neuroativos e composições compreendendo os mesmos |
LT3488852T (lt) | 2013-08-23 | 2021-02-25 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai, kompozicijos, ir jų naudojimas |
HRP20221294T1 (hr) | 2014-05-29 | 2023-03-03 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, njihovi pripravci i uporabe |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
EP3188734A4 (en) | 2014-09-02 | 2018-01-10 | The Texas A&M University System | Method of treating organophosphate intoxication |
HUE051488T2 (hu) | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
CN108350021A (zh) | 2015-09-08 | 2018-07-31 | 视点医疗公司 | 用于治疗眼科疾病的化合物和制剂 |
WO2017049044A1 (en) | 2015-09-16 | 2017-03-23 | Bartolucci Giampiero | Ursodeoxycholic acid and brain disorders |
MX2018004376A (es) | 2015-10-16 | 2018-08-01 | Marinus Pharmaceuticals Inc | Formulaciones inyectables de neuroesteroides que contienen nanoparticulas. |
WO2017087864A1 (en) | 2015-11-20 | 2017-05-26 | Sage Therapeutics, Inc. | Compounds and methods of their use |
JOP20170059B1 (ar) | 2016-03-08 | 2021-08-17 | Sage Therapeutics Inc | ستيرويدات وتركيبات نشطة عصبيًا واستخداماتها |
US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
DK3481845T3 (da) | 2016-07-11 | 2023-11-27 | Sage Therapeutics Inc | C17, c20 og c21 substituerede neuroaktive steroider og deres anvendelsesmetoder |
WO2018013615A1 (en) * | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
SG11201901445TA (en) | 2016-08-23 | 2019-03-28 | Sage Therapeutics Inc | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
CA3068462A1 (en) | 2017-06-23 | 2019-12-27 | The Board Of Trustees Of The University Of Illinois | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
CN111065394B (zh) | 2017-08-31 | 2023-03-31 | 武田药品工业株式会社 | 中枢神经***病症的治疗 |
WO2019051264A1 (en) | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
JP7312169B2 (ja) | 2017-11-10 | 2023-07-20 | マリナス ファーマシューティカルズ インコーポレイテッド | 遺伝性てんかん性障害の処置に使用するガナキソロン |
KR20200104349A (ko) | 2017-12-22 | 2020-09-03 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 조성물 및 방법 |
WO2019126741A1 (en) | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
JP7438956B2 (ja) | 2018-02-11 | 2024-02-27 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ステロイド系誘導体モジュレーター、その製造方法及び応用 |
UY38213A (es) | 2018-05-04 | 2019-10-31 | Acerus Pharmaceuticals Corp | Derivados de neuroesteroides y usos de estos |
MX2021006618A (es) | 2018-12-05 | 2021-09-23 | Sage Therapeutics Inc | Esteroides neuroactivos y sus metodos de uso. |
WO2020210117A1 (en) * | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
JP2022538301A (ja) | 2019-06-27 | 2022-09-01 | セージ セラピューティクス, インコーポレイテッド | Cns障害を治療するための組成物及び方法 |
AR119305A1 (es) | 2019-06-27 | 2021-12-09 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de los trastornos del snc |
-
2020
- 2020-05-29 KR KR1020217040463A patent/KR20220016098A/ko unknown
- 2020-05-29 AU AU2020284110A patent/AU2020284110A1/en active Pending
- 2020-05-29 JP JP2021570911A patent/JP2022534424A/ja active Pending
- 2020-05-29 JO JOP/2021/0293A patent/JOP20210293A1/ar unknown
- 2020-05-29 BR BR112021024033A patent/BR112021024033A2/pt unknown
- 2020-05-29 US US16/887,887 patent/US11643434B2/en active Active
- 2020-05-29 CR CR20210629A patent/CR20210629A/es unknown
- 2020-05-29 CA CA3139554A patent/CA3139554A1/en active Pending
- 2020-05-29 MA MA056046A patent/MA56046A/fr unknown
- 2020-05-29 WO PCT/US2020/035210 patent/WO2020243488A1/en active Application Filing
- 2020-05-29 CN CN202080052646.8A patent/CN114206900A/zh active Pending
- 2020-05-29 AR ARP200101529A patent/AR119047A1/es unknown
- 2020-05-29 EP EP20746378.7A patent/EP3976628A1/en active Pending
- 2020-05-29 MX MX2021014515A patent/MX2021014515A/es unknown
- 2020-05-29 PE PE2021001958A patent/PE20230244A1/es unknown
- 2020-05-29 SG SG11202112391UA patent/SG11202112391UA/en unknown
- 2020-06-01 TW TW109118340A patent/TW202110457A/zh unknown
-
2021
- 2021-11-25 IL IL288410A patent/IL288410A/en unknown
- 2021-11-25 CO CONC2021/0015890A patent/CO2021015890A2/es unknown
- 2021-11-29 CL CL2021003166A patent/CL2021003166A1/es unknown
- 2021-12-16 EC ECSENADI202191076A patent/ECSP21091076A/es unknown
-
2022
- 2022-09-02 US US17/902,159 patent/US20230250128A1/en active Pending
-
2023
- 2023-07-28 DO DO2023000152A patent/DOP2023000152A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2021015890A2 (es) | 2021-11-30 |
CA3139554A1 (en) | 2020-12-03 |
BR112021024033A2 (pt) | 2022-02-08 |
SG11202112391UA (en) | 2021-12-30 |
DOP2023000152A (es) | 2024-01-15 |
ECSP21091076A (es) | 2022-01-31 |
MA56046A (fr) | 2022-04-06 |
KR20220016098A (ko) | 2022-02-08 |
US20200377547A1 (en) | 2020-12-03 |
IL288410A (en) | 2022-01-01 |
PE20230244A1 (es) | 2023-02-07 |
US20230250128A1 (en) | 2023-08-10 |
AR119047A1 (es) | 2021-11-17 |
EP3976628A1 (en) | 2022-04-06 |
TW202110457A (zh) | 2021-03-16 |
US11643434B2 (en) | 2023-05-09 |
JP2022534424A (ja) | 2022-07-29 |
CN114206900A (zh) | 2022-03-18 |
MX2021014515A (es) | 2022-03-22 |
AU2020284110A1 (en) | 2021-11-25 |
CL2021003166A1 (es) | 2022-09-30 |
JOP20210293A1 (ar) | 2023-01-30 |
WO2020243488A1 (en) | 2020-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20210629A (es) | Esteroides neuroactivos y composiciones de estos | |
SA519401947B1 (ar) | مُعدِّل منظم التوصيل عبر الأغشية للتليف الكيسي، تركيبات صيدلية، طرق علاج، وعملية لتحضير المُعدِّل | |
MX2023002006A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
MX2023009610A (es) | Esteroides neuroactivos, y su metodo de uso. | |
MX2022001828A (es) | Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr). | |
MX2021007504A (es) | Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos. | |
MX2023005098A (es) | Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central. | |
MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
WO2020257549A3 (en) | Compounds for treatment of pd-l1 diseases | |
MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
MX2010007375A (es) | Nuevos derivados de lupano. | |
MX2020001719A (es) | Inhibidores macrocíclicos de mcl-1 y metodos de uso. | |
MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
MX2022016343A (es) | Esteroides neuroactivos y composiciones de estos. | |
EP4321519A3 (en) | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders | |
MX2020011089A (es) | Compuestos antiproliferacion y usos de los mismos. | |
MX2021012105A (es) | Compuestos de pirrol. | |
MX2021007247A (es) | Derivados de rapamicina. | |
PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
PH12019502652A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
TW200635592A (en) | Pyridyl-substituted spiro-hydantoin compounds and use thereof | |
ZA202203108B (en) | Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections |